Company Filing History:
Years Active: 2013-2018
Title: Min Li: Innovator in Antibody Therapeutics
Introduction
Min Li is a prominent inventor based in Sudbury, MA (US), known for his significant contributions to the field of antibody therapeutics. With a total of 3 patents, he has made strides in developing innovative solutions for cancer treatment.
Latest Patents
His latest patents focus on EPHA2 receptor antagonist antibodies. These antagonistic antibodies specifically bind to and inhibit Class A Eph receptors. The patents also include cytotoxic conjugates, pharmaceutical compositions, and kits that comprise these antibodies. Furthermore, methods of use for antibodies that specifically bind to the EphA2 receptor are detailed. These antibodies and their fragments are designed to antagonize the effects of growth factors on tumor cell growth and survival, with minimal agonistic activity. They may be utilized in treating tumors that express elevated levels of A class Eph receptors, including breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma, and pancreatic cancer. Additionally, the patents describe cytotoxic conjugates that combine a cell binding agent with a cytotoxic agent, therapeutic compositions, and methods for using these conjugates in disease treatment.
Career Highlights
Min Li is currently associated with Sanofi, a leading global biopharmaceutical company. His work at Sanofi emphasizes the development of innovative therapeutic solutions that address critical health challenges.
Collaborations
He collaborates with notable colleagues, including Veronique Blanc and Claudia Fromond, to advance research and development in antibody therapeutics.
Conclusion
Min Li's innovative work in the field of antibody therapeutics showcases his commitment to improving cancer treatment options. His patents reflect a deep understanding of the complexities of tumor biology and the potential of targeted therapies.